
Ovarian cancer treatment on fast track for FDA approval as chemo alternatives emerge: 'We're making progress'
Fox News
Ovarian cancer drug RC88 by RemeGen received FDA approval for Phase 2 clinical trials. Gynecologic oncologist Dr. Brian Slomovitz and other experts weigh in on the drug's potential.
As ovarian cancer develops, the level of mesothelia increases — which gives RC88 its "unique" target. Angelica Stabile is a lifestyle writer for Fox News Digital.
The drug received fast-track designation (FTD) for the treatment of "platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancers," the company confirmed to Fox News Digital.
More Related News

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












